Top 50 Cell Line Development in LATAM

Nuwacell specializes in the research, development, and production of induced pluripotent stem cell (iPSC)-derived therapies for clinical applications. The company addresses the need for effective cell-based treatments in regenerative medicine by providing scalable and reliable cell therapy products.

Atelier Meats utilizes proprietary scaffold technology and tissue engineering to produce structured cuts of cultivated meat without harming animals. This approach addresses the demand for ethically sourced, sustainable meat alternatives while reducing environmental impact.

Swift Solar develops lightweight and flexible photovoltaic cells using engineered perovskite tandem technology, which efficiently absorbs the solar spectrum to maximize power output. By manufacturing these cells domestically, the company reduces carbon emissions and mitigates supply chain risks, enabling scalable production to meet global energy demands.

Cell Farm is the first clean meat startup in LATAM, utilizing a standardized biotechnology process to cultivate meat from animal stem cells. This approach addresses the environmental and ethical concerns associated with traditional meat production by providing a sustainable alternative that reduces resource consumption and animal welfare issues.

EdgeQ develops a Base Station-on-a-Chip that integrates 4G and 5G technologies for small and macro cell deployments, enabling customizable and field-deployable solutions compliant with 3GPP standards. This technology addresses the need for efficient, low-power wireless infrastructure to enhance network coverage and support mission-critical applications in various environments.

Edge Animal Health develops novel therapeutics and vaccines for veterinary medicine by utilizing gene engineering tools and advanced cell therapies, addressing significant unmet healthcare needs in animals. The company applies biotechnological advancements from human health to improve disease prevention and treatment in pets and livestock.

Eugit develops novel tissue targeting therapies for complex diseases. The company leverages expertise in computational genomics and immunology to design precise therapeutic approaches. Their focus is on creating treatments that selectively engage specific biological targets within diseased tissues.

Exomas develops treatments for neurodegenerative diseases using neural stem cell-derived exosomes (CBSD-EXO). This technology stimulates the proliferation of existing neural stem cells and promotes neuroplasticity by generating new neurons. The goal is to restore mental and motor functions impaired by neurological damage.

Elegen utilizes proprietary cell-free DNA synthesis technology to produce long, complex, linear DNA up to 7 kb with 99.999% accuracy, eliminating the need for cloning. This rapid synthesis, delivered in 6 to 8 business days, addresses the critical bottleneck in DNA supply for synthetic biology applications, significantly reducing project timelines and costs.

Isla Technologies develops a minimally invasive cell implant that regulates insulin production for individuals with poorly controlled type 1 diabetes. This technology aims to reduce the frequency of severe hypoglycemic episodes and improve overall glycemic control.

Develops senoblockers, a novel class of therapeutics that target epigenetic regulators to reverse cellular senescence and restore stem cell activity. This approach addresses the decline in regenerative capacity and the accumulation of senescent cells, which are key contributors to age-related diseases.

Engage Bio develops Tethosomes, a non-viral DNA platform designed to overcome potency and toxicity limitations in genetic medicine delivery. This technology utilizes LNP delivery to express a proprietary protein that tethers therapeutic DNA to the nucleus, achieving over 100x expression while remaining non-immunogenic. The platform enables potent, durable, and safely redosable DNA medicines scalable for therapeutic applications across gene replacement and oncology.

resistanceBio develops oncology drugs that focus on understanding and preventing drug resistance by mimicking the long-term evolution of cancer in a controlled environment. Their platform enables the identification of resistance pathways and the development of longer-lasting therapies, addressing the critical issue of treatment-resistant cancer that contributes to 90% of cancer mortality.

Trebe Biotech utilizes insect larvae as biofactories to produce high-quality recombinant proteins and vaccines, offering a sustainable and cost-effective alternative to traditional bioreactor methods. This approach addresses the need for rapid production of bioproducts, particularly in response to emerging health challenges in both human and veterinary medicine.

The startup specializes in identifying bioactive ribonucleic acid (RNA) from natural sources using machine learning and bioinformatics techniques. This enables researchers to enhance human health and resilience in response to environmental stressors through the application of RNA technologies.

Fecundis develops sperm-enhancing technologies that improve sperm functionality and increase embryo quality, based on over 20 years of research in reproductive biology. The company addresses the inefficiencies and challenges of traditional fertility treatments by providing scalable solutions that integrate into clinical workflows.

ANCOR TECMIN enhances non-ferrous metal electrowinning and electrorefining operations with advanced electrolytic cell technology and custom composite capping boards. They also provide tankhouse rehabilitation services to optimize performance and product quality for mineral processing plants.

Elytron utilizes biotechnology and artificial intelligence to analyze vast collections of microorganisms and their derivatives, predicting their efficacy for crop protection and nutrition. This approach accelerates the development of biopesticides, addressing the need for sustainable agricultural solutions that reduce reliance on chemical pesticides.

Embryoxite develops an AI-powered platform that analyzes embryo metabolomic data, genetic profiles, and morphokinetic imaging to assess implantation potential in pre-implantation embryos. This technology addresses the high failure rate of embryo implantation in IVF procedures by providing objective, data-driven insights that enhance selection accuracy and improve pregnancy outcomes.

UpDairy utilizes precision fermentation to produce animal-free dairy proteins by incorporating cow genes into fungi, which then generate these proteins in bioreactors. This technology addresses the environmental impact of traditional dairy farming by significantly reducing greenhouse gas emissions, water usage, and land requirements.

TwoStep Therapeutics develops novel modalities to enhance the efficacy and expand the applicability of targeted cancer therapies. The company focuses on engineering drug conjugates designed for improved systemic delivery and tumor penetration. This approach aims to increase therapeutic windows for precision oncology treatments.

The startup is a biopharmaceutical company focused on developing novel therapeutics specifically targeting chronic gastrointestinal conditions through advanced drug formulation techniques. By addressing the unmet medical needs in this area, the company aims to improve patient outcomes and quality of life for those suffering from these persistent disorders.

Single Helix Genomics has developed an automated, portable device that delivers therapeutics on demand, utilizing advanced genomic technologies for precise treatment applications. This device addresses the need for immediate and personalized therapeutic solutions in various medical settings, enhancing patient care and treatment efficiency.

Nat4Bio develops organic coatings using cell-free biological formulations derived from native microorganisms to extend the shelf life of fresh produce. Their technology significantly reduces spoilage and waste in global supply chains, addressing the critical issue of food loss, which affects up to 50% of fruits and vegetables.

This biotech startup produces highly pure enzymes using recombinant DNA repair technology derived from Antarctic extremophiles, enabling large-scale replication of active ingredients. Their offerings provide clinicians with effective alternatives for skin health and rejuvenation in the cosmetic and pharmaceutical industries.

This company develops a modular platform for the on-demand self-assembly of smart, multifunctional nanobiomaterials. Guided by a One Health approach, they are building business units focused on disease detection, prevention, and treatment. Their proprietary technology leverages expertise in protein engineering, immunology, and vaccinology to address global health challenges.

Siolta Therapeutics develops targeted live biotherapeutics using its Precision Symbiotics Platform™ to create therapeutic microbial consortia that address inflammatory diseases. The company combines clinical data and microbial science to target disease-specific mechanisms, aiming to meet the high unmet medical needs in this area.

Cache DNA develops next-generation biopreservation technologies to support breakthroughs in the life sciences. The company focuses on storing biomolecules at unprecedented scales, moving beyond traditional freezer storage methods. This advanced preservation supports high-quality biospecimens necessary for clinical research, assay development, and personalized therapies.

Clear Labs is a biotechnology firm that utilizes a genomics system to enhance diagnostic accuracy in clinical and application sectors. The company addresses the complexity of traditional diagnostic processes by providing streamlined genomic analysis, enabling faster and more reliable results.

This biotech startup specializes in the production of dried flowers, full-spectrum extracts, and purified pharmaceutical-grade cannabinoids for medical applications. By providing research and development services focused on the stabilization and characterization of these cannabinoids, the company enables laboratories to access high-quality medical cannabis for pharmaceutical use.

Guska develops synthetic RNA oncolytic virus therapies that precisely target and eliminate cancer cells while stimulating the immune system. This approach offers a more effective and less harmful alternative to traditional cancer treatments by enhancing the body's ability to fight tumors.

The startup develops small molecule drugs that target nuclear receptors and master transcription factors to regulate cellular metabolism. This approach aims to enhance patient health by providing effective treatments for metabolic disorders.

Aptah Biosciences develops the RNA WiCo™ technology, an oligo-based approach that modulates U1-snRNP function to prevent premature transcription termination. This mechanism restores full-length RNA expression, correcting fundamental cellular mechanisms disrupted in various diseases. The technology aims to treat conditions like cancer, ophthalmology, autoimmune, and neurodegenerative disorders by ensuring proper gene expression fidelity.

Rosebud Biosciences develops targeted therapies for rare pediatric genetic diseases using patient-specific organoid models. The company engineers micropatterned 2.5D organoids from induced pluripotent stem cells that replicate individual genetic mutations for drug screening. This platform enables the high-throughput testing of small molecules, gene therapies, and RNA therapeutics against complex developmental disorders.

This biotechnology company develops customized fungal precision prebiotics to improve gut health. They offer a data-driven approach, enabling customers to enhance their gut microbiome through personalized solutions.

BioHeuris combines synthetic biology and gene editing to create herbicide-resistant crops that enable sustainable weed management. This approach reduces the reliance on toxic herbicides and mitigates the evolution of herbicide-resistant weeds, promoting environmental sustainability in agriculture.

This company develops genetically modified black soldier fly strains to create a highly efficient and sustainable biomanufacturing platform. Their technology produces a diverse range of high-quality recombinant proteins for pharmaceuticals, vaccines, and industrial enzymes. This approach offers competitive pricing while supporting responsible production and consumption goals.

This agricultural bioscience company develops gene identification and characterization technologies to enhance crop yields and improve food security. By validating discoveries in prototype plants and forming partnerships with seed companies, they enable clients to maintain agricultural productivity amid climate challenges.

The startup develops preventive treatments that enhance the natural immunity of fish, utilizing immunostimulants to improve resistance against bacterial pathogens and diseases. This approach replaces antibiotics, leading to higher survival rates and growth in aquaculture while providing cost-effective and sustainable solutions for fish cultivators.

Cellva develops high-performance ingredients using proprietary microencapsulation technology to enhance stability and functionality. Their solutions improve nutrient delivery, enable fat reduction, and preserve flavor across various applications. This technology allows for the creation of clean-label, scientifically validated ingredients that optimize product performance and cost.

Longevity Medical Institute offers advanced regenerative therapies and integrated diagnostics to improve healthspan and vitality. They provide personalized treatment protocols using stem cell and exosome therapies, alongside AI-enhanced imaging and comprehensive laboratory analysis for age-related and chronic conditions.

The startup operates a research and development platform that utilizes sustainable biotechnological processes to extract and produce natural active compounds for health, beauty, and skin care applications. By providing cost-effective and consistent natural ingredients, the company addresses the industry's demand for environmentally friendly and efficient solutions.

Terraflos integrates the innovation cycle from discovering new active principles in plants to transforming them into evidence-based food, supplement, and dermocosmetic products optimized by AI. The company focuses on maximizing plant power through conscious science and technology across three key segments: supplements, food, and SkinTech. They utilize an Agentic AI called JEN to coordinate their network of B2B companies, ensuring alignment in purpose, vision, and execution for health and well-being solutions.

Unibaio develops advanced biomaterials using natural polymers like chitosan derived from sustainable sources. The company engineers microparticles and hydrogels for applications in tissue engineering and agriculture. These materials function as carriers and additives to enhance cell growth, protect active ingredients, and improve soil moisture control.

The startup utilizes a bio-based technological platform that employs genetic engineering tools and microalgae to produce valuable proteins and compounds, such as hirudin, which is traditionally sourced from sponges. This approach provides a sustainable and cost-effective solution for companies seeking hard-to-find biochemical compounds.

This biotechnology company develops novel health treatments utilizing genetically engineered viruses. Their platform focuses on repurposing viruses, such as the Zika virus, into therapeutic agents. The company is advancing a pipeline of biotherapeutics based on this specialized viral vector technology.

The startup has developed a clinical research platform that utilizes machine learning to target the biological processes of aging, facilitating the discovery of therapies for age-related diseases such as cardiovascular and neurodegenerative conditions. By enabling pharmaceutical companies to enhance medical treatments, the platform addresses the need for more effective interventions in aging-related health issues.

Veloz Bio utilizes molecular farming techniques to produce animal-free alternative proteins, addressing the environmental and ethical concerns associated with traditional animal agriculture. By leveraging plant-based systems for protein synthesis, the company aims to provide sustainable and scalable protein sources for the growing global demand.

CellRep develops an AI-powered platform to discover and validate compounds for non-genetic cell reprogramming. This approach optimizes cellular function to enhance therapeutic potential, addressing limitations in current cell therapies like CAR-T treatments. The company provides an end-to-end pipeline from target discovery through preclinical validation for applications in oncology and longevity.

This startup provides biotechnology services focused on developing industrial yeast strains and optimizing fermentation processes through advanced yeast metabolism and genetics research. Their solutions enable the yeast and fermentation industries to produce environmentally friendly products using renewable resources, addressing the need for sustainable manufacturing practices.